Latest University Health Network Stories
OTTAWA, April 22, 2013 /CNW/ - Today in Ottawa, Hélène Campbell announced the Give2Live Campaign, a social media effort that uses crowdfunding to support the needs of those waiting for transplants throughout Canada. "Many patients waiting for an organ transplant at Toronto General Hospital and other transplant centres are required to live within two hours of the hospital," said Ms. Campbell. "More often than not, this means uprooting from their home and finding new housing...
A team of Canadian and international cancer researchers led by Dr. Brenda Gallie at the Princess Margaret Cancer Centre, University Health Network (UHN), has discovered a new type of retinoblastoma, a rapidly developing eye cancer that affects very young babies– a finding that can immediately change clinical practice and optimize care for these children. The finding, published online today in Lancet Oncology, is a breakthrough in recognizing that a single cancer gene (an oncogene) drives...
In a world first, a team of researchers at the Krembil Neuroscience Centre and the University Health Network have shown that Deep Brain Stimulation (DBS) in patients with chronic, severe and treatment-resistant Anorexia Nervosa (anorexia) helps some patients achieve and maintain improvements in body weight, mood, and anxiety. The results of this trial, entitled Deep Brain Stimulation of the Subcallosal Cingulate Area for Treatment-Refractory Anorexia Nervosa: A Phase I Pilot Trial, are...
Biggest Ever Private Donation to Cancer Research in Canada TORONTO, Jan. 21, 2013 /PRNewswire/ - Canadian philanthropists Emmanuelle Gattuso, Allan Slaight and the Slaight family made history today with a $50 million gift to The Princess Margaret Cancer Foundation. The extraordinary donation is the biggest ever private gift to cancer research in Canadian history and will advance the Princess Margaret Cancer Centre's Personalized Cancer Medicine initiative. Ms. Gattuso and Mr....
Largest healthcare initiative of its kind in Canada launched to conquer cancer in our lifetime TORONTO, April 12, 2012 /PRNewswire/ - Amidst the skirl of the pipes and a glistening 400-ounce bar of solid gold symbolizing a new gold standard in cancer care, The Princess Margaret Hospital Foundation today announced its new 'BELIEVE IT!' campaign -- a BILLION DOLLAR CHALLENGE to accelerate Personalized Cancer Medicine at The Princess Margaret. "We live in the Golden Age of cancer...
TORONTO, April 3, 2012 /PRNewswire/ -- Mobile Integrated Systems, Inc (OTCBB:LOTID), operating through its wholly-owned subsidiary Mobilotto Systems, Inc. ("Mobilotto"), today announced the deployment of a mobile lottery application for The Princess Margaret Hospital Foundation Lotteries. This Android application debuts the first mobile lottery application in Canada for a charitable lottery and allows users to register, receive notifications and order tickets directly from their...
Low oxygen levels in tumors can be used to predict cancer recurrence in men with intermediate-risk prostate cancer even before they receive radiation therapy. The clinical research, led by radiation oncologists at the Princess Margaret Hospital (PMH) Cancer Program, University Health Network (UHN) is published online today in Clinical Cancer Research, a journal of the American Association for Cancer Research (doi: 10.1158/1078-0432.CCR-11-2711). "We've not only shown that men do worse...
TORONTO, Feb. 14, 2012 /PRNewswire/ - Health technology company Infonaut (www.infonaut.ca), a MaRS client, announced it has signed a contract with the University Health Network to test its real-time disease surveillance system, Hospital Watch Live, at the Toronto General Hospital. Designed to assist hospitals in controlling and stopping the spread of infectious organisms, Hospital Watch Live has been installed on the multi-organ transplant unit, an area of the hospital where all...
For men diagnosed with low-risk, localized prostate cancer, being treated with the drug dutasteride ("Avodart") delays disease progression and initiating active treatment, and also reduces anxiety, show the results of a three-year international clinical trial led by Dr. Neil Fleshner, Head of the Division of Urology, University Health Network (UHN). The findings are published online today in The Lancet. "The results prove that using active surveillance plus dutasteride is a viable, safe...
Treating ovarian cancer with the drug bevacizumab ("Avastin") delays the disease and may also improve survival, show the results of an international clinical trial co-led by Drs. Amit Oza of the Princess Margaret Cancer Program, University Health Network and Timothy Perren, St James's Institute of Oncology, Leeds, UK. The findings, published today in the New England Journal of Medicine, report that the drug halted the cancer's return for two months overall. However, for women with the...
